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ABSTRACT  21 
Chagas disease  has the highest prevalence of any parasitic disease in the Americas, affecting 6 to 7 million 22 
people. Conventional diagnosis requires a well-equipped laboratory with experienced personnel.  The 23 
development of new diagnostic tools that are easy to use and adapted to the reality of affected populations 24 
and health systems is still a significant challenge. The main objective of this study was to measure T. cruzi 25 
infection status using saliva samples of infected subjects. Blood and saliva samples from 20 T.cruzi-26 
seropositive individuals and 10 controls were tested for T. cruzi infection using two different commercial 27 
serological tests. We have shown that detection of Chagas infection  is possible using saliva samples, 28 
supporting the potential use of saliva to diagnose Chagas disease in humans. This method could provide a 29 
simple, low-cost but effective tool in the diagnosis of T. cruzi infection. The non-invasive nature of it makes it 30 
particularly well suited to endemic areas.   31 
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INTRODUCTION 61 
Chagas disease (CD) is a major public health problem in Latin America, affecting approximately 6 to 7 million 62 
people. In addition, travel and immigration patterns have increased the relevance of T. cruzi infection outside 63 
of endemic areas1,2,3. T. cruzi can be transmitted to humans by reduviid insects that inhabit housing made of 64 
mud, thatch, and other natural materials in endemic areas4, by blood transfusion, organ transplant from 65 
infected donors5, congenital from mother to infant6 and by ingestion of food or drink contaminated by 66 
infected triatomines7.  67 
 68 
CD still faces multiple challenges. There are no preventive vaccines for human or veterinary use and the two 69 
available treatments are not optimal as they are plagued by side effects and  inconsistent efficiency8,9,10,11. 70 
Additionally, the diagnosis of this infection confronts several limitations. In the acute phase of the infection, 71 
diagnosis is based on the microscopic detection of trypomastigotes in blood. However, during the chronic 72 
phase of the infection parasite persistence is low and the detection of T. cruzi using this method is difficult 73 
and unreliable. Serology is the gold standard for T. cruzi infection diagnosis during the chronic phase of the 74 
disease. At least two different serological methods (preferably based on different antigens) are used to detect 75 
the presence of IgG antibodies against T. cruzi antigens. Currently, no single assay for chronic T. cruzi infection 76 
has shown enough sensitivity and specificity to be used alone for diagnosis12. 77 
 78 
CD particularly affects poor rural and peri-urban areas of Latin America, where health-care access is limited. 79 
Developing new diagnostic tools which are easy to use and adapted to the reality of affected populations and 80 
health systems, is still a substantial need13. The purpose of this study is to address this challenge by exploring 81 
the detection of T. cruzi infection status using saliva samples.  82 
 83 
 84 
 85 
 86 
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MATERIAL AND METHODS 87 
Ethics statement 88 
The study protocol was approved by the Ethics Committee of the Hospital Clinic of Barcelona and the 89 
Scientific Committee of the Barcelona Institute for Global Health (ISGlobal). Individual written informed 90 
consent was obtained from all study participants before the collection of the samples. 91 
Design and setting 92 
The study was designed as a pilot project to detect T. cruzi infection status using saliva of infected individuals. 93 
A total of 20 T. cruzi-seropositive individuals were enrolled in one group (GA), and 10 T. cruzi-seronegative 94 
individuals in another group (GB).  GB was included as a negative control group. GA patients were originally 95 
from Latin America countries where CD is endemic. Among them, 10 received benznidazole treatment 96 
between 2005 and 2015 (all of them completed the treatment regime), and 10 of them did not receive 97 
treatment during the length of the study. GB subjects came from different areas of the world. 98 
Selection of subjects 99 
Inclusion criteria: adult subjects (over 18 and less than 50 years-old); weight over 40 kg, with serologic tests 100 
confirming or excluding T. cruzi infection. All the participants were recruited at the Center for International 101 
Health at the Hospital Clinic of Barcelona, Spain.  102 
Participants 103 
Subjects of both genders and aged between 18 and 50 years old were included in the study.  104 
 105 
Sample collection and procedures 106 
(a) Blood samples: 10 mL blood sample per individual was collected for diagnosis of T. cruzi infection in 107 
serum. Samples were centrifuged at 1600 g for 10 minutes at room temperature. 108 
(b) Saliva samples: Subjects also provided 10 mL of unstimulated saliva samples. Saliva samples were 109 
centrifuged using ultrafiltration membranes (Amicon Ultra-15 devices) at 4000 g for 15 minutes at room 110 
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temperature.  111 
 112 
ELISA Tests 113 
300 microliters (µL) of concentrated saliva samples and 10 µL of blood serum were used to perform the 114 
serological test. Two different commercial serological tests were used: Bioelisa CHAGAS from Biokit (BioELISA 115 
Chagas; Biokit S.A., Lliçà d'Amunt, Barcelona, Spain), and DRG Trypanosoma cruzi IgG (DRG International Inc., 116 
Springfield, U.S.A).  117 
Data analysis 118 
Statistical analysis was performed by analysis of variance and unpaired t test using the GraphPad PRISM 5.0 119 
software.  120 
 121 
RESULTS 122 
We first detected T. cruzi infection status with the current serological tests using enzyme-linked 123 
immunosorbent assay (ELISA) from Biokit. As expected, seropositive patients showed higher levels of IgG 124 
anti-T. cruzi antibodies compared to T. cruzi-seronegative subjects (Figure 1). 125 
Previous to running ELISA assays on the saliva samples of T. cruzi infected individuals, we tested whether a 126 
filtered and therefore a more concentrated saliva sample would exhibit a higher sensitivity than an unfiltered 127 
sample. Filtered saliva samples showed higher levels of response to T. cruzi antigen than their unfiltered 128 
counterparts, although these differences were not statistically significant (Figure 2A). Additionally, different 129 
volumes of filtered saliva samples were tested and the results showed a higher sensitivity when using 300 µl 130 
compared to other volumes (Figure 2B).   131 
Then, we tested 20 T. cruzi-seropositive and 10 T. cruzi-seronegative serum and saliva samples using the same 132 
test. Results are summarized in figure 3. T. cruzi-seropositive subjects presented higher levels of IgG anti T. 133 
cruzi antibodies compared to T. cruzi-seronegative subjects, using serum or saliva samples (Figure 3A). ELISA 134 
results demonstrated consistency between serum and saliva samples. The salivary test presented a specificity 135 
6 
 
of 100%: all T. cruzi-seronegative individuals were negative using saliva as a sample. The sensitivity of the test 136 
was 70%: 6 of the 20 T. cruzi-seropositive individuals were negative using saliva as a source. 4 of these 137 
subjects were previously treated with benznidazole, and 2 of them were not previously treated. ELISA’s cut-138 
off value was computed by the usual cut-off formula of the form “mean + 3 standard deviation of negative 139 
controls”.  140 
 We also compared levels of T. cruzi antibodies for both saliva and serum of previously treated and untreated 141 
seropositive subjects. Differences in levels of serum IgG anti T. cruzi antibodies were not found between 142 
treated and  untreated  individuals. Interestingly, we found differences in levels of T. cruzi antibodies between 143 
treated and  untreated individuals using saliva (Figure 3B). However, these results were not statistically 144 
significant.  145 
 146 
DISCUSSION 147 
The most common method of diagnosing CD is detecting serum antibodies against parasite antigens mainly 148 
using ELISA tests. However, there are some limitations of using serum as a diagnostic sample. Blood 149 
collection is invasive, and it demands specially trained personnel.  150 
Saliva has the potential to become a first line diagnostic sample of choice. The use of this fluid for diagnostic 151 
purposes is increasing in popularity: it is easy to collect, store and transport, it does not require highly trained 152 
personnel, and it is safer for medical staff to handle compared to other body fluids. In addition, it is 153 
noninvasive and the donation process is relatively stress free, minimizing donor discomfort. This can help 154 
improve access to diagnosis and treatment for people living in rural areas far from healthcare centers. These 155 
characteristics make salivary diagnosis especially valuable for vulnerable populations. In addition, analysis of 156 
saliva may provide a cost-effective approach for the screening of large populations14,15. Due to its many 157 
potential advantages, salivary diagnosis provides an attractive alternative to more invasive, time-consuming, 158 
complicated, and expensive diagnostic approaches.  159 
Pinho et al. explored this area of research in 199916 for T. cruzi infection, showing that detection of T. cruzi 160 
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infection was possible using saliva samples. Our data confirms these findings, and thus supports saliva as a 161 
possible source of detection of CD.  162 
Although our results have shown consistency between serum and saliva samples of T. cruzi-seropositive and 163 
T. cruzi-seronegative subjects, the low sensitivity of the ELISA test using saliva as a source of diagnostic could 164 
represent a challenge. It is common to find low concentrations of molecules in saliva compared to blood15. 165 
This weakness could be partially overcome using ultrafiltration membranes to concentrate saliva samples.  166 
Our results have shown differences in the levels of IgG T. cruzi antibodies between previously treated 167 
subjects and untreated patients. Currently, the gold standard for evaluating treatment efficacy is the 168 
seroconversion of conventional serological tests, which may take years to decades to assess17. Although this is 169 
a preliminary finding, saliva could play an important role in evaluating treatment efficacy.  170 
 171 
CONCLUSIONS 172 
T. cruzi specific salivary IgG detection provides a simple, low-cost but effective tool in the diagnosis of the 173 
disease. The non-invasive nature of this method makes it particularly well suited to endemic areas. The 174 
salivary test presented a specificity of 100%. Unfortunately, the sensitivity of the test was lower: 30% of T. 175 
cruzi-seropositive individuals were negative using saliva as a diagnostic sample. 176 
In the future, saliva could play a key role in diagnosis of T. cruzi infection and evaluation of treatment efficacy. 177 
Additional studies exploring other salivary molecules such as IgA anti T. cruzi levels could be helpful, due to 178 
the high concentration of this immunoglobulin in saliva. More research is needed with larger sample sizes to 179 
further investigate this method, which has the potential to revolutionize diagnosis and treatment of Chagas 180 
disease.  181 
 182 
 183 
 184 
 185 
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Figure 1: Serum IgG response to T. cruzi antigen in T. cruzi-seropositive and T. cruzi-
seronegative subjects. 
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Figure 2A: Saliva IgG response to T. cruzi antigen using ultrafiltration membranes.  
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Figure 2B: Saliva IgG response to T. cruzi antigen in T. cruzi-seropositive and T. cruzi-
seronegative subjects using different sample volumes 
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Figure 3A: Serum and saliva IgG response to  T. cruzi antigen in  T. cruzi-seropositive and T. cruzi-
seronegative subjects. 
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Figure 3B: Serum and saliva IgG response to T. cruzi antigen in T. cruzi-seropositive subjects 
previously treated with benznidazole and T. cruzi-seropositive subjects untreated.  
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Table 1: Age and gender of study participants. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GB Age Gender 
      European controls 
39 Female 
32 Male 
31 Male 
35 Female 
26 Female 
Endemic countries 
controls 
28 Female 
43 Male 
30 Female 
39 Male 
28 Female 
GA Age Gender 
Untreated patients 
 
38 Female 
31 Female 
44 Male 
44 Female 
42 Female 
39 Female 
44 Male 
42 Female 
34 Male 
33 Female 
Treated patients  
 
54 Female 
46 Female 
43 Female 
50 Female 
33 Female 
49 Female 
40 Female 
48 Female 
50 Female 
41 Female 
